Conmana Bests Chemotherapy in Progression-Free Survival for Lung Cancer
BY Jason Harris
According to the results of a recent study conducted in China, patients with stage 3B/4 non-small cell lung cancer (NSCLC) saw a 3.3-month increase in median progression-free survival (PFS) when taking Conmana (icotinib) compared to those who were taking chemotherapy.
Keytruda Shows Benefit in Small Cell Lung Cancer
BY Jason Harris
The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.
Identifying Rare Biomarker Could Help a Subset of Patients With Lung Cancer
BY Danielle Bucco
RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.
Questions Remain on Immunotherapy Use in Lung Cancer
BY Danielle Bucco
David R. Gandara, M.D., discusses the latest immunotherapy advances in lung cancer, as well as the next steps toward optimizing the use of these agents.
Expert Talks the Future in Metastatic Lung Cancer Treatment
BY Silas Inman
The treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC) is changing, as more emphasis is being placed on drug combinations and biomarkers, says Roy S. Herbst, M.D., Ph.D.
Examining the Role of Stress in Lung Cancer
BY Syed Jafri, M.D.
Syed Jafri, M.D., an assistant professor at the University of Texas McGovern School of Medicine, discusses the potential role that stress could play in lung cancer diagnoses.
Treatment Guidelines Updated for Advanced Lung Cancer
BY Jason Harris
ASCO updated guidelines for the treatment of certain patients with advanced non-small cell lung cancer (NSCLC). 
Expert Discusses Lung Cancer Gene Editing
BY Gina Columbus
CRISPR technology may one day lead the field in turning off genetic mutations that cause numerous diseases, such as lung cancer. CURE spoke with Monte Winslow, Ph.D., about CRISPR's current use in mouse models.
Expert Talks Molecular Targets in Lung Cancer
BY Gina Columbus
“The goal is to identify more of these driving genetic alterations and to come up with treatments that we can target,” said Das in an interview during an interview with CURE.
The American Lung Association Seeks to End Stigma
BY Thomas Keenan
When patients are diagnosed with lung cancer, one of the first questions they're often asked is, "Do you have a history of smoking?" 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Lung CURE discussion group.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Non-Small Cell Lung Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of non-small cell lung cancer.
Small Cell Lung Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of small cell lung cancer.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Lung Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing lung cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Lung Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for lung cancer.
//For side ad protocol